초록접수 현황
| 17F-138 | 포럼 발표 |
Surgical Outcomes of Small Cell Lung Cancer Patients - Comparison with Pure Small Cell Lung Cancer Versus Mixed or Synchronous Small Cell Lung Cancer
Han Pil Lee, Min Kyun Kang, Byung Kwon Chong, Jin San Bok, Geun Dong Lee, Se Hoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Seung Il Park, Dong Kwan Kim
Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea
Purpose : Surgical outcomes and prognostic factors for resection of limited stage SCLC were evaluated. Histologic subgroup analysis was performed for comparison of pure SCLC and mixed or synchronous (combined) SCLC.
Methods : Between January, 2006 and December, 2016, a total of 110 patients who underwent pulmonary resection for treatment of limited stage SCLC were analyzed retrospectively. 79 patients had pure SCLC and 31 patients had combined SCLC.
Results : There were significant differences were observed with regard to their baseline and clinical characteristics except postoperative hospital stay (6.8 vs 9.2 days, p = 0.043). The median follow-up duration was 20.4 months (range, 1 to 132 months). 34 patients (30.9%) experienced recurrence. There were 2 (1.8%) surgical mortalities. 49 (44.5%) patients died during follow-up; 18 died of disease progression and the other 31 died of non-cancerous cause. There was no significant difference in 3-year overall (57.5% vs 50.8%, p = 0.415) and disease-free survival rate (55.4% vs 50.8%, p = 0.348) between the pure SCLC group and the combined SCLC group. Multivariate analysis revealed that N2 stage (p < 0.001), absence of adjuvant therapy (p < 0.001) were risk factors for the overall survival. 3-year overall (61.4% vs 25.9%, p = 0.001) and disease-free survival rate (69.9% vs 18.8%, p < 0.001) were significantly greater in the patients with stage I/II than those with stage III.
Conclusion : Pulmonary resection of the limited stage SCLC is applicable. Histological variation seems no effects on overall and disease-free survival. Postoperative adjuvant therapy may be needed for a better prognosis.
Methods : Between January, 2006 and December, 2016, a total of 110 patients who underwent pulmonary resection for treatment of limited stage SCLC were analyzed retrospectively. 79 patients had pure SCLC and 31 patients had combined SCLC.
Results : There were significant differences were observed with regard to their baseline and clinical characteristics except postoperative hospital stay (6.8 vs 9.2 days, p = 0.043). The median follow-up duration was 20.4 months (range, 1 to 132 months). 34 patients (30.9%) experienced recurrence. There were 2 (1.8%) surgical mortalities. 49 (44.5%) patients died during follow-up; 18 died of disease progression and the other 31 died of non-cancerous cause. There was no significant difference in 3-year overall (57.5% vs 50.8%, p = 0.415) and disease-free survival rate (55.4% vs 50.8%, p = 0.348) between the pure SCLC group and the combined SCLC group. Multivariate analysis revealed that N2 stage (p < 0.001), absence of adjuvant therapy (p < 0.001) were risk factors for the overall survival. 3-year overall (61.4% vs 25.9%, p = 0.001) and disease-free survival rate (69.9% vs 18.8%, p < 0.001) were significantly greater in the patients with stage I/II than those with stage III.
Conclusion : Pulmonary resection of the limited stage SCLC is applicable. Histological variation seems no effects on overall and disease-free survival. Postoperative adjuvant therapy may be needed for a better prognosis.
책임저자: Dong Kwan Kim
Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea
발표자: Han Pil Lee, E-mail : inis.lee@gmail.com